pharmaceutical investing Johnson & Johnson Announces CAPLYTA Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study 10 November
pharmaceutical investing Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer 08 November
pharmaceutical investing Johnson & Johnson announces ICOTYDE® delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide 07 November
